Octreotide
- Half-Life (t½)
- SC: 1.5h · IV: 1.5h · IM: 1.5h
- Formula
- C49H66N10O10S2
- Molecular Weight
- 1019.2 g/mol
- Aliases
- SMS 201-995, Sandostatin, Sandostatin LAR
Pharmacological Mechanism
Cyclic octapeptide with a disulfide bridge (Cys-2 – Cys-7) and D-Phe, D-Trp, Thr-ol modifications — producing 30× longer t½ than native somatostatin (1.5 h vs 2 min) and SSTR2 > SSTR5 selectivity. Suppresses GH + IGF-1 (acromegaly), inhibits hormone release from functional neuroendocrine tumours (carcinoid, VIPoma, glucagonoma), and reduces portal pressure acutely (variceal bleeding). LAR formulation: biodegradable PLGA microspheres release drug over ~4 weeks.
Half-Life & Elimination Curve (SC: 1.5h · IV: 1.5h · IM: 1.5h)
Plasma (SC)t½ Decay (1.5h)
- 0×t½0h100% (3.07 µg/L)
- 1×t½1.5h50% (1.53 µg/L)
- 2×t½3h25% (0.767 µg/L)
- 3×t½4.5h12.5% (0.383 µg/L)
- 4×t½6h6.3% (0.192 µg/L)
- 5×t½7.5h3.1% (0.0958 µg/L)
Dosing Guidelines
- Subcutaneous (SC): Typical 100 mcg (Range: 50–200 mcg)
- Intramuscular (IM): Typical 100 mcg (Range: 50–200 mcg)
- Intravenous (IV): Typical 100 mcg (Range: 50–200 mcg)
Pharmacokinetic Parameters
- Subcutaneous (SC): Bioavailability (F): 100% · Volume of Distribution (Vd): 21 L · Absorption (ka): 2 h⁻¹ (t½ka ≈ 21m) [PMID 2876508]
- Intravenous (IV): Bioavailability (F): 100% · Volume of Distribution (Vd): 21 L [PMID 2876508]
- Intramuscular (IM): Bioavailability (F): 100% · Volume of Distribution (Vd): 21 L [PMID 26076191]
Pathways It Modulates
Target Organ Systems
Chemical Structure & Identifiers
- InChIKey: DEQANNDTNATYII-OULOTJBUSA-N
- SMILES: C[C@H]([C@H]1C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=CC=C4)NC(=O)[C@@H](CC5=CC=CC=C5)N)C(=O)N[C@H](CO)[C@@H](C)O)O
References